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parathyroid hormone.
Background. The kidney is one of the affected organs in-
volved in the clinical symptoms of parathyroid hormone (PTH)-
related disorders, like primary hyperparathyroidism and famil-
ial hypocalciuric hypercalcemia. The molecular mechanism(s)
underlying alterations in renal Ca2+ handling in these disorders
is poorly understood.
Methods. Parathyroidectomized and PTH-supplemented rats
and mice infused with the calcimimetic compound NPS R-467
were used to study the in vivo effect of PTH on the expres-
sion of renal transcellular Ca2+ transport proteins, including the
epithelial Ca2+ channel transient receptor potential, vanilloid,
member 5 (TRPV5), calbindins, and the Na+/Ca2+-exchanger
(NCX1). In addition, the effect of PTH on transepithelial Ca2+
transport in rabbit connecting tubule/cortical collecting duct
(CNT/CCD) primary cultures was determined.
Results. Decreased PTH levels in parathyroidectomized
rats or NPS R-467–infused mice, resulted in reduced ex-
pression of these proteins, which is consistent with dimin-
ished Ca2+ reabsorption, causing the development of the
observed hypocalcemia. PTH supplementation of parathy-
roidectomized rats restored the expression of the renal Ca2+
transport machinery and serum Ca2+ levels, independent of
serum 1,25-dihydroxyvitamin D3 levels and renal vitamin D
or Ca2+-sensing receptor mRNA abundance. Inhibition of the
PTH-stimulated transepithelial Ca2+ transport by the TRPV5-
specific inhibitor ruthenium red reduced the PTH-stimulated
expression of calbindin-D28K and NCX1 in rabbit CNT/CCD
primary cultures.
Conclusion. PTH stimulates renal Ca2+ reabsorption through
the coordinated expression of renal transcellular Ca2+ transport
proteins. Moreover, the PTH-induced stimulation is enhanced
by the magnitude of the Ca2+ influx through the gatekeeper
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TRPV5, which in turn facilitates the expression of the down-
stream Ca2+ transport proteins. Therefore, the renal transcellu-
lar Ca2+ transport proteins, including TRPV5, could contribute
to the pathogenesis of PTH-related disorders.
Primary hyperparathyroidism is a common endocrine
disorder characterized by elevated parathyroid hormone
(PTH) levels that are inappropriate to the level of serum
Ca2+ [1]. This underlines the importance of PTH as an
essential component of Ca2+ homeostasis. Secretion of
PTH from the parathyroid glands is regulated by the
ambient Ca2+ concentration, sensed by the parathyroid
Ca2+-sensing receptor [2]. The Ca2+-sensing receptor is
activated by high serum Ca2+ concentrations and couples
to the inhibition of PTH secretion. Inactivating mutations
of the Ca2+-sensing receptor result in familial hypocal-
ciuric hypercalcemia or neonatal severe hyperparathy-
roidism [3], whereas autosomal-dominant hypocalcemia
is caused by activating mutations [4]. These disorders
demonstrate the predominant role of the Ca2+-sensing
receptor in controlling parathyroid gland function and,
hence, the role of PTH in regulating systemic Ca2+ bal-
ance. From the clinical symptoms of these PTH-related
disorders, like hypo- or hypercalciuria and renal stone
formation, it is clear that also renal Ca2+ handling is
affected.
Regulation of Ca2+ reabsorption in the kidney is cru-
cial for the maintenance of normal serum Ca2+ lev-
els and occurs via paracellular as well as transcellular
routes. Transcellular or active Ca2+ reabsorption is the
primary target for regulation by calciotropic hormones,
including 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and
PTH. Active Ca2+ reabsorption takes place in the dis-
tal convoluted tubule (DCT) and connecting tubule
(CNT) of the kidney. Luminal Ca2+ enters these tubu-
lar cells via the epithelial Ca2+ channels, transient re-
ceptor potential, vanilloid, members 5 and 6 (TRPV5
and TRPV6), is then transported across the cell in
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association with Ca2+-carrier proteins (i.e., calbindins)
and is finally extruded into the blood stream via the
Na+/Ca2+-exchanger (NCX1) and the plasma membrane
Ca2+-ATPase (PMCA1b) [5–8]. PTH receptors have
been detected throughout the kidney, as well as in the
actively Ca2+ transporting tubules DCT and CNT [9, 10].
Therefore, the contribution of these Ca2+ transport pro-
teins to the altered Ca2+ handling in PTH-related disor-
ders seems likely.
Treatment of primary hyperparathyroidism has been
limited to surgical ablation (parathyroidectomy) of the
affected glands. A new approach for treating primary
hyperthyroidism is to target the mechanisms that regu-
late the secretion of PTH. The Ca2+-sensing receptor is
the first step in this process. In the last decade synthetic
compounds, referred to as calcimimetic compounds, have
been developed [11, 12]. Type I calcimimetics are full
agonists of the Ca2+-sensing receptor, whereas type II
calcimimetics are small organic compounds that, upon
binding to the Ca2+-sensing receptor, enhance the sen-
sitivity of the Ca2+-sensing receptor to Ca2+ in an al-
losteric fashion, thereby altering PTH secretion by the
parathyroid glands. In this way, the type II calcimimetic
compounds may provide a novel therapy for treating hy-
perparathyroidism [11, 12].
The present study aims to gain insight into the molecu-
lar mechanism(s) underlying the alterations in renal Ca2+
handling in PTH-related disorders. To this end, the in
vivo effect of PTH on the expression of proteins involved
in renal transcellular Ca2+ reabsorption was examined.
Here, we demonstrated that PTH affects renal Ca2+
handling through the coordinated regulation of the ex-
pression of renal transcellular Ca2+ transport proteins.
Moreover, the PTH-induced increase in Ca2+ influx
through TRPV5 facilitates the expression of downstream
Ca2+ transport proteins, thereby further emphasizing the
gatekeeper function of TRPV5.
METHODS
Animals
In experiment 1, male Sabra rats, weighing 250 g, had
free access to normal rat chow and water. After ac-
climatization, rats were either sham-operated (N= 4)
or parathyroidectomized (N= 8) by cauterization. After
7 days, Alzet osmotic minipumps were implanted subcu-
taneously (model 2001) (Durect Corporation, Cupertino,
CA, USA). Sham-operated rats received vehicle solution
[2% (wt/vol) cysteine HCl] and parathyroidectomized
rats received either vehicle solution or bovine PTH
1-34 (Sigma Chemical Co., St. Louis, MO, USA) at a
rate of 0.25 U PTH 1-34/hour (parathyroidectomized +
PTH) for 7 days. In experiment 2, Male C57BL6 mice, 8
weeks of age, were fed standard chow and given water
ad libitum. After acclimatization, mice were divided in
four groups of five animals each. Mice were anesthetized
and an Alzet model 1007D osmotic minipump (Durect
Corporation) was implanted subcutaneously. The pump
infused the calcimimetic compound NPS R-467 (NPS
Pharmaceuticals, Salt Lake City, UT, USA) at a dose
of 10, 30, or 100 lmol per kg body weight per day
or vehicle solution [45% (wt/vol) aqueous solution of
2-hydroxypropyl-b-cyclodextrin]. At the end of the treat-
ment periods, animals were sacrificed, and blood and
kidney samples were taken. The animal ethics board of
the University Medical Center Nijmegen and Hadassah
University Hospital Jerusalem approved all animal ex-
perimental procedures.
Primary cultures of rabbit kidney CNT/cortical collecting
duct (CCD)
Rabbit kidney CNT/CCD cells were immunodissected
from New Zealand white rabbits (5 weeks of age) with
monoclonal antibody R2G9 and set in primary culture
on permeable filter supports (0.33 cm2) (Corning-Costar,
Cambridge, MA, USA) as described previously in detail
[13]. The culture medium was a 1:1 mixture of Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F-12 medium
(Gibco, Paisley, UK) supplemented with 5% (vol/vol) de-
complemented fetal calf serum (FCS), 10 lg/mL ciproxin,
10 lg/mL nonessential amino acids (Gibco), 5 lg/mL
insulin, 5 lg/mL transferrin, 50 nmol/L hydrocortisone,
70 ng/mL prostaglandin E1 (PGE1), 50 nmol/L Na2SeO3,
5 pmol/L triiodothyronine, and 5 lmol/L indomethacin,
equilibrated with 5% CO2 95% air at 37◦C. Two days after
seeding, the cells were incubated for 120 hours with and
without 100 nmol/L bovine PTH 1-34 (Sigma Chemical
Co.) at the apical (total volume 100 lL) and basolateral
(total volume 600 lL) compartment, whereas 10 lmol/L
ruthenium red was added only to the apical side. Trans-
port assays were performed with confluent monolayers
7 days after seeding the cells.
Determination of transepithelial Ca2+ transport
Confluent monolayers of primary cultures were
washed and preincubated in a physiologic salt solution
containing (mmol/L) 140 NaCl, 2 KCl, 1 K2HPO4, 1
KH2PO4, 1 MgCl2, 1 CaCl2, 5 glucose, 5 L-alanine, 10
Hepes/Tris (pH 7.4), and 5 lmol/L indomethacin for
15 minuts at 37◦C, adding 10 lmol/L of the TRPV5-
mediated Ca2+-influx blocker ruthenium red [14] to the
apical side. Subsequently, the monolayers were incubated
with 100 nmol/L PTH and 10 lmol/L ruthenium red for a
further 90 minutes to measure transepithelial Ca2+ trans-
port. At the end of the incubation period, 25 lL samples
were collected in duplicate from the apical compartment
and assayed for Ca2+ concentration using a colorimetric
assay kit (Boehringer, Mannheim, Germany). Under the
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outlined experimental conditions, these polarized renal
cells exhibit transcellular Ca2+ transport, of which the
net apical-to-basolateral Ca2+ flux is linear with time for
at least 3 hours [13, 15]. Ca2+ reabsorption is expressed
in nmol/hour−1/cm−2.
Analytical procedures
Serum Ca2+ concentrations were analyzed using a
colorimetric assay kit as described previously [16].
Serum phosphorus levels were measured on a Hi-
tachi autoanalyzer (Hitachi Corp., Tokyo, Japan).
PTH levels were determined using either a rat PTH
(1-34) immunoradiometric assay or a mouse intact
PTH enzyme-linked immunosorbent assay (ELISA) kit
(Immunotopics, San Clemente, CA, USA). 1,25(OH)2D3
was measured by immunoextraction followed by quan-
titation by 125I-radioimmunoassay (RIA) (IDS, Boldon,
UK) [17].
RNA isolation and quantitative polymerase chain
reaction (PCR)
Total RNA from kidney and primary CNT/CCD
cells was isolated using Trizol Reagent (Gibco BRL,
Life Technologies, Breda, The Netherlands) according
to the manufacturer’s protocol. Total DNAse-treated
RNA (2 lg) was reverse-transcribed using Moloney
murine leukemia virus reverse transcriptase (MMLV-RT)
(Gibco BRL) as described previously [18]. Expression of
TRPV5, TRPV6, calbindin-D28K, calbindin-D9K, NCX1,
PMCA1b, Ca2+-sensing receptor, and vitamin D recep-
tor mRNA, as well as mRNA levels of the housekeeping
gene hypoxanthine-guanine phosphoribosyl transferase
(HPRT), as an endogenous control, were determined
by quantitative real-time PCR on an ABI Prism 7700
Sequence Detection System (PE Biosystems, Rotkreuz,
Switserland). The primer and probe sequences of Ca2+-
sensing receptor, vitamin D receptor, TRPV5, calbindin-
D28K, and NCX1 are depicted in Table 1. Other sequences
have been described previously [19, 20].
Immunohistochemistry
Kidney tissue was cut into pieces, placed in 1%
(wt/vol) periodate-lysine-paraformaldehyde fixative for
2 hours at room temperature, and incubated overnight
at 4◦C in phosphate-buffered saline (PBS) containing
15% (wt/vol) sucrose. Subsequently, kidney tissues were
frozen in liquid nitrogen and 7 lm sections were cut for
the staining procedure. For detection of TRPV5 abun-
dance or colocalization of TRPV5 and Ca2+-sensing re-
ceptor, kidney sections were stained with guinea pig anti-
TRPV5 antiserum (1:50) as described previously [19] and
rabbit antihuman Ca2+-sensing receptor antibody (1:500)
(antiserum 4641, a gift from NPS Pharmaceuticals).
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Table 2. Effect of parathyroidectomy and parathyroid hormone (PTH) supplementation on serum parameters in Sabra ratsa
Sham Parathyroidectomy Parathyroidectomy + PTH
PTH pg/mL 43.5 ± 14.7 6.1 ± 2.9b 14.4 ± 4.6
Ca2+ mmol/L 2.89 ± 0.06 1.61 ± 0.07c 2.51 ± 0.04d
Phosphorus mmol/L 1.59 ± 0.06 2.15 ± 0.04c 1.82 ± 0.10d
1,25(OH)2D3 pmol/L 375 ± 9 261 ± 29b 234 ± 13b
aSham, sham-operated; parathyroidectomy + PTH, parathyroidectomy supplemented with 0.25 U PTH (1-34)/hour. Data are presented as mean ± SE (N= 4).
bP < 0.05 versus sham.
cP < 0.05 versus sham and parathyroidectomy + PTH.
dP < 0.05 versus sham and parathyroidectomy.
To visualize TRPV5 and Ca2+-sensing receptor, sections
were stained with goat antiguinea Alexa 488–conjugated
anti-IgG (1:300) (Sigma Chemical Co.) and goat an-
tirabbit Alexa 594–conjugated anti-IgG (1:300) (Sigma
Chemical Co.), respectively. Sections were visualized by
confocal laser scanning microscopy (MRC-1024) (Bio-
Rad, Richmond, CA, USA). To quantify TRPV5 protein
expression, digital images of each kidney section were
taken with a Zeiss Axioskop microscope (Carl Zeiss, Inc.,
Thornwood, NY, USA) and the integrated optical den-
sity was measured by computer analysis with the Image-
Pro Plus version 3.0 software (Media Cybernetics, Silver
Spring, MD, USA).
Immunoblotting
For protein analysis, frozen kidney tissue and the
cultured cells were homogenized in ice-cold solubiliza-
tion buffer as previously described [21]. Total kidney
protein fractions (10 lg) or cell protein fractions (4 lL)
were separated on 12% or 16.5% (wt/vol) sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels and blotted to polyvinylidine difluo-
ride (PVDF)-nitrocellulose membranes (Immobilon-P)
(Millipore Corporation, Bedford, MA, USA). Blots
were incubated with calbindin-D28K antibody (1:10,000)
(Sigma Chemical Co.), calbindin-D9K antibody (1:3000)
(Swant, Bellinzona, Switzerland), or Na+/K+-ATPase
antibody (1:10,000) (kindly provided by J.B. Koenderink,
Department of Biochemistry, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands)
[22] and thereafter with peroxidase-conjugated goat
antirabbit antibody (1:2000) (Sigma Chemical Co.). Im-
munoreactive protein was detected using the enhanced
chemiluminescence (ECL) method as described by
the manufacturer (Amersham, Buckinghamshire, UK).
Protein expression was quantified by computer-assisted
densitometry with the use of the Image-Pro Plus version
3.0 software (Media Cybernetics).
Statistical analysis
Values are expressed as mean ± SE. Statistical sig-
nificance of differences between groups was determined
by analysis of variance (ANOVA) followed by pair-wise
comparisons using the method of least significant differ-
ence. An unpaired t test was used for comparisons be-
tween control and 100 lmol/kg body weight/day groups.
Differences in means with P < 0.05 were considered sta-
tistically significant.
RESULTS
Rescue of parathyroidectomy-induced hypocalcemia by
PTH supplementation in rats
Surgical removal of the parathyroid glands resulted
in the reduction of serum PTH levels, whereas serum
PTH levels tended to increase after infusion with 0.25
U PTH (1-34)/hour (Table 2). Moreover, parathyroidec-
tomy caused a severe hypocalcemia and hyperphos-
phatemia, which were partially restored by PTH sup-
plementation (Table 2). In addition, serum 1,25(OH)2D3
levels were decreased in parathyroidectomized rats, but
no changes were observed after PTH supplementation
(Table 2).
Effect of PTH on renal expression of Ca2+ transporters
To investigate the effect of PTH on renal Ca2+ han-
dling, the expression of genes encoding Ca2+ trans-
port proteins involved in transcellular Ca2+ reabsorption
was examined using quantitative real-time PCR. Surgi-
cal removal of the parathyroid glands in rats induced
a 70% decrease in TRPV5 mRNA levels, which were
completely normalized after PTH infusion (Fig. 1A).
In contrast, no significant effects were detected on the
expression of TRPV6 mRNA between sham-operated,
parathyroidectomy, and parathyroidectomy + PTH rats
(Fig. 1B). Similar to TRPV5 expression, mRNA tran-
scripts encoding for calbindin-D28K were down-regulated
in parathyroictomized rats and partially restored in the
PTH-supplemented animals (Fig. 1C). The expression of
calbindin-D9K was not measured, because it is not de-
tectable in rat kidney. In addition, parathyroidectomy
reduced the expression of NCX1 (Fig. 1D), whereas
PMCA1b mRNA levels were not altered (Fig. 1E). No
differences were observed in Ca2+-sensing receptor or vi-
tamin D receptor mRNA levels after parathyroidectomy
or subsequent infusion of PTH (Fig. 1F and G).
Subsequently, examination of the expression of re-
nal Ca2+ transport proteins by immunohistochem-
istry revealed a marked decrease in TRPV5 protein
1712 van Abel et al: PTH-dependent regulation of renal TRPV5
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Fig. 2. Effect of parathyoidectomy (PTX) and supplementation with parathyroid hormone (PTH) (1-34) on protein expression levels of transient
receptor potential, vanilloid, member 5 (TRPV5) in rat kidney. Immunofluorescence staining of kidney cortex sections of sham, parathyroidectomy,
and parathyroidectomy + PTH rats showing the abundance of TRPV5 (A), which was quantified by computer analysis of the integrated optical
density and expressed in relative percentages (B). Glomeruli (G) are depicted in the images. Immunoblots of samples (10 lg protein each) from
homogenates of kidney tissue were labeled with antibodies against calbindin-D28K (D). Expression of calbindin-D28K protein was quantified
by computer-assisted densitometry analysis and expressed in relative percentages (C). Sham (), sham-operated rats; parathryoidectomy (),
parathyroidectomized rats + PTH (), parathyroidectomized rats supplemented with 0.25 U PTH (1-34)/hour. Data are presented as means ± SE
(N= 4). ∗P < 0.05 versus sham; #P < 0.05 versus all.
abundance in response to parathyroidectomy, as indi-
cated by the reduced immunopositive staining (Fig. 2A).
As observed for TRPV5 mRNA expression, PTH
supplementation increased the protein abundance in
the parathyroidectomized animals. The correspond-
ing integrated optical density analysis confirmed the
significant decline in TRPV5 protein abundance after
parathyroidectomy (Fig. 2B). Furthermore, Western blot
analysis of calbindin-D28K consistently demonstrated a
down-regulation in the protein abundance in parathy-
roidectomized rats and a subsequent normalization after
PTH infusion (Fig. 2D). Densitometric analysis of the in-
tensity of the immunocomplexes confirmed this decrease
in calbindin-D28K protein expression after parathyroidec-
tomy (Fig. 2C).
NPS R-467 treatment reduced serum PTH and Ca2+
levels in mice
Infusion of the calcimimetic compound NPS R-467 for
7 days reduced serum PTH levels. Furthermore, this re-
duction was associated with a fall in serum Ca2+ con-
centrations and an increase in serum phosphorus levels.
Measurements of circulating 1,25(OH)2D3 levels re-
vealed no effect of NPS R-467 treatment compared with
vehicle (Table 3).
Reduction in renal Ca2+ transport proteins after NPS
R-467 treatment
To address the molecular mechanism responsible for
the decreased serum Ca2+ levels upon NPS R-467
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Table 3. Effect of treatment with NPS R-467 on serum parameters in male C57BL6 micea
Control 10 lmol/kg 30 lmol/kg 100 lmol/kg
Parthyroid hormone pg/mL 20.8 ± 2.5 14.6 ± 1.2b 13.0 ± 0.6b 10.8 ± 1.2b
Ca2+ mmol/L 2.42 ± 0.02 2.34 ± 0.02 2.26 ± 0.02b 2.18 ± 0.06b,c
Phosphorus mmol/L 2.07 ± 0.19 2.72 ± 0.09b 2.72 ± 0.12b 2.71 ± 0.06b
1,25(OH)2D3 pmol/L 309 ± 59 326 ± 14 307 ± 10 227 ± 27
aControl, treated with vehicle; 10 lmol/kg, treated with NPS R-467 at 10 lmol/kg body weight/day; 30 lmol/kg, treated with NPS R-467 at 30 lmol/kg body
weight/day; 100 lmol/kg, treated with NPS R-467 at 100 lmol/kg body weight/day. Data are presented as means ± SE (N= 5).
bP < 0.05 versus control.
cP < 0.05 versus 10 lmol/kg.
infusion, the expression of genes encoding Ca2+ transport
proteins involved in renal transcellular Ca2+ reabsorption
was examined. TRPV5 mRNA expression was consis-
tently lower in kidneys of NPS R-467–treated mice com-
pared to controls (Fig. 3A), whereas no differences in the
expression of TRPV6 were detected (Fig. 3B). Similar to
TRPV5 expression, mRNA levels of both calbindin-D28K
and calbindin-D9K were down-regulated in response to
calcimimetic treatment (Fig. 3C and D). In addition,
NPS R-467 treatment inhibited the expression of NCX1
(Fig. 3E), whereas PMCA1b mRNA levels were only
down-regulated at 100 lmol/kg body weight/day com-
pared to control animals (Fig. 3F). Infusion with NPS
R-467 induced a reduction in the expression of Ca2+-
sensing receptor mRNA compared to control mice
(Fig. 3G), while no differences were detected in the
mRNA expression of vitamin D receptor (Fig. 3H).
Subsequently, the reduced mRNA levels of TRPV5 af-
ter NPS R-467 treatment were confirmed by immunohis-
tochemical analysis. As shown in Figure 4A, the staining
intensity of the TRPV5 protein was remarkably reduced
in kidney cortex sections of NPS R-467–treated mice.
Figure 4B depicts the corresponding integrated optical
density analysis and demonstrated that TRPV5 protein
expression is significantly down-regulated. In addition,
the immunoblots shown in Figure 4C and E demonstrated
a down-regulation of both calbindin-D28K and calbindin-
D9K proteins in the NPS R-467–treated mice com-
pared to controls, which was confirmed by densitometry
(Fig. 4D and F).
Localization of the Ca2+-sensing receptor in mouse
kidney cortex
In addition to the presence in the parathyroid glands,
the Ca2+-sensing receptor is also expressed in kidney. In
Figure 5, the distribution of Ca2+-sensing receptor im-
munopositive staining in kidney cortex was compared
to the TRPV5 localization. The distribution of Ca2+-
sensing receptor was most abundant in the basolateral
region of the thick ascending limb (Fig. 5A, arrowheads).
Importantly, immunopositive staining for Ca2+-sensing
receptor (Fig. 5A, asterisks, and C) was also observed
in TRPV5 expressing DCT and CNT (Fig. 5B, aster-
isks, and D). TRPV5 was predominantly localized along
the apical domain of these segments, whereas Ca2+-
sensing receptor–specific staining revealed a more diffuse
pattern.
Inhibition of PTH-stimulated transepithelial Ca2+ trans-
port decreased calbindin-D28K and NCX1 expression
To determine the molecular mechanism responsible
for the regulation of the Ca2+ transport proteins, pri-
mary cultures of the rabbit CNT/CCD grown to conflu-
ence on permeable supports were employed. Figure 6A
shows that in the absence of any stimulus, these mono-
layers exhibit a net apical-to-basolateral Ca2+ flux of
43 ± 2 nmol/hour−1/cm−2. Treatment with PTH (100
nmol/L) had a stimulatory effect on transepithelial Ca2+
reabsorption (Fig. 6A). Apical addition of the Ca2+
channel blocker ruthenium red (10 lmol/L) completely
inhibited basal transepithelial Ca2+ reabsorption and
PTH-stimulated Ca2+ transport (Fig. 6A). Furthermore,
the stimulatory effect of PTH on Ca2+ transport was ac-
companied by increased mRNA expression of TRPV5,
calbindin-D28K and NCX1 (Fig. 6B to D). Importantly,
this PTH-induced increase in calbindin-D28K and NCX1
mRNA expression was significantly reduced in mono-
layers cultured in the presence of ruthenium red, while
the mRNA expression of TRPV5 was unaltered after
ruthenium red treatment. Immunoblot and densitomet-
ric analysis of the intensity of the immunocomplexes of
calbindin-D28K confirmed this decrease in calbindin-D28K
protein expression after ruthenium red treatment using
the Na+/K+-ATPase as an internal control for equal load-
ing (Fig. 6E and F).
DISCUSSION
The present study demonstrated that PTH stimulates
renal Ca2+ reabsorption through the coordinated expres-
sion of transcellular Ca2+ transport proteins. Moreover,
our results indicated that by up-regulating the expres-
sion of the TRPV5, the Ca2+ influx is increased, which in
turn facilitates the regulation of the down-stream Ca2+
transport proteins. These findings further emphasize the
gatekeeper function of TRPV5.
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Fig. 4. Effect of NPS R-467 on protein expression levels of transient receptor potential, vanilloid, member 5 (TRPV5) in the kidney. Immunoflu-
orescence staining of kidney cortex sections of control and treated mice showing the abundance of TRPV5 (A), which was quantified by computer
analysis of the integrated optical density and expressed in relative percentages (B). Glomeruli (G) are depicted in the images. Immunoblots of
samples (10 lg protein each) from homogenates of kidney tissue were labeled with antibodies against calbindin-D28K (C) and calbindin-D9K
(E). Expression of calbindin-D28K and calbindin-D9K protein was quantified by computer-assisted densitometry analysis and expressed in relative
percentages (D and F). Control (), mice treated with vehicle; treated (), mice treated with NPS R-467 at 100 lmol/kg body weight/day. Data are
presented as means ± SE (N= 5). ∗P < 0.05 versus control.
The available therapy for treating primary hyper-
parathyroidism, a disease that so far has resisted pharma-
cologic intervention, has been limited to surgical removal
of the affected glands. Here, we showed that parathy-
roidectomy in rats results in marked reduction of serum
PTH levels and hyperphosphatemia, a well-known symp-
tom in hypoparathyroidism [23–25]. In addition, parathy-
roidectomy induced the concomitant decrease of renal
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Fig. 5. Immunofluorescence localization of
the Ca2+-sensing receptor and transient
receptor potential, vanilloid, member 5
(TRPV5). Double staining of a mice kid-
ney cortex section showing staining for Ca2+-
sensing receptor (A) and TRPV5 (B). The as-
terisks indicate the tubular segments, where
Ca2+-sensing receptor and TRPV5 colocal-
ize. The tubules depicted by the arrowheads
stained intensely for Ca2+-sensing receptor,
but were negative for TRPV5. G is glomeru-
lus. Colocalization of Ca2+-sensing receptor
(C) and TRPV5 (D) in distal convoluted
tubule (DCT) and connecting tubule (CNT)
of kidney cortex section.
mRNA and protein abundance of TRPV5, calbindin-
D28K, and NCX1. As demonstrated by the hypercalciuria
present in TRPV5 knockout mice, the decline in renal
expression of transcellular Ca2+ transport proteins in the
present experiment is indicative for a decreased capacity
of active Ca2+ reabsorption [26] and relates to the devel-
opment of the observed hypocalcemia. Serum PTH lev-
els tended to increase after PTH supplementation, which
was apparently sufficient to restore the expression of the
renal Ca2+ transport proteins and increase serum Ca2+
concentrations. Moreover, these findings imply that PTH,
in concert with its well-established effect on Ca2+ resorp-
tion from bone [27], increases renal Ca2+ reabsorption by
up-regulating the expression of TRPV5 and other Ca2+
transport proteins, thereby maintaining the Ca2+ balance.
In agreement with this finding, PTH receptors have been
detected throughout the kidney, as well as in the actively
Ca2+ transporting tubules DCT and CNT [9]. Thus, PTH
is capable of stimulating active Ca2+ transport in kidney
through receptor-mediated actions.
Calcimimetic compounds provide a novel non-surgical
therapy for hyperparathyroidism by enhancing the sensi-
tivity of the Ca2+-sensing receptor to extracellular Ca2+,
thereby suppressing the secretion of PTH and normal-
izing serum Ca2+ levels [11]. Studies of inherited disor-
ders caused by mutations in Ca2+-sensing receptor clearly
suggested that this receptor is the mechanism for Ca2+-
mediated regulation of PTH secretion [28]. To determine
whether NPS R-467 could indeed effectively lower PTH
levels and affect renal Ca2+ handling, mice were treated
for 7 days with the calcimimetic compound NPS R-467.
In agreement with previous findings, NPS R-467 success-
fully decreased serum PTH levels [12, 29]. In addition
to the suppression of PTH, serum Ca2+ concentrations
were reduced after NPS R-467 treatment, whereas serum
phosphate levels were increased. Interestingly, a similar
concurrent down-regulation of the expression of the re-
nal Ca2+ transport proteins (i.e., TRPV5, calbindin-D28K
and calbindin-D9K, NCX1, and PMCA1b) was observed
in kidneys of NPS R-467–treated mice as for the parathy-
roidectomized rats, and indicative for a decreased capac-
ity of active Ca2+ reabsorption. This finding is consistent
with complementary findings in other studies. A short-
term use of the type II calcimimetic compound NPS R-
568 was previously associated with an increase in urinary
Ca2+ excretion in hypercalcemic patients with primary
hyperparathyroidism [30]. Recently, Fox et al [abstract;
Fox J et al, J Am Soc Nephrol SA-FC179, 2003] showed
that injections with NPS R-467 in rats increased the frac-
tional excretion of Ca2+. Taken together, our findings
suggested that PTH stimulates the coordinated expres-
sion of transcellular Ca2+ transport proteins in kidney,
which could contribute to increased Ca2+ reabsorption
and positively affect Ca2+ balance.
Active Ca2+ reabsorption is a primary target for the
regulation by calciotropic hormones. We have previously
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shown that the expression of TRPV5, as well as the other
proteins involved in active Ca2+ transport, is positively
regulated by 1,25(OH)2D3 and other hormones, like es-
trogens [19, 31, 32]. 1,25(OH)2D3 is synthesized primarily
as a result of the conversion of 25-hydroxyvitamin D3 by
the renal enzyme 25-hydroxyvitamin D3-1a-hydroxylase
(1a-OHase). PTH is the major regulator of renal 1a-
OHase [33]. In turn, 1,25(OH)2D3 controls parathyroid
gland growth and suppresses the synthesis and secre-
tion of PTH. Moreover, 1,25(OH)2D3 and its analogues
are frequently used as treatment for secondary hyper-
parathyroidism [34, 35]. Therefore, 1,25(OH)2D3 could
be responsible for the observed effect on the expres-
sion of Ca2+ transport proteins. However, the decline in
TRPV5, calbindin-D28K and calbindin-D9K and NCX1
expression after NPS R-467 treatment was not due to
decreased levels of 1,25(OH)2D3. In contrast, the de-
crease in serum PTH levels in the parathyroidectomized
rats did result in reduced 1,25(OH)2D3 levels. However,
PTH supplementation did not alter serum 1,25(OH)2D3
levels, but was sufficient to concomitantly elevate the
expression of TRPV5, calbindin-D28K, and NCX1. This
supports a regulatory mechanism primarily controlled by
PTH. However, a possible mechanism by which PTH
could affect expression is an increased sensitivity for
1,25(OH)2D3 via elevated vitamin D receptor expres-
sion. 1,25(OH)2D3 exerts its biologic actions by binding
to the vitamin D receptor and the response in the target
tissues to 1,25(OH)2D3 is directly related to the vitamin D
receptor abundance [33]. Parathyroidectomy, PTH sup-
plementation, or NPS R-467 infusions did, however, not
change vitamin D receptor mRNA levels, suggesting that
the alterations in renal Ca2+ transport protein expres-
sion were not associated with changes in renal vitamin D
receptor expression. Together, these findings imply that
PTH stimulates renal Ca2+ reabsorption by up-regulation
of the expression of TRPV5 and other Ca2+ transport
proteins, independently of 1,25(OH)2D3.
In addition to the presence in parathyroid glands, the
Ca2+-sensing receptor is also expressed in other cells
involved in systemic Ca2+ homeostasis. Notable among
these are certain epithelial cells in kidney cortex, particu-
larly those in the cortical thick ascending limb (TAL) and
DCT [36]. Therefore, the observed effect on serum Ca2+
levels after NPS R-467 infusion could also be explained by
a direct action of the Ca2+-sensing receptor on the Ca2+
transport mechanisms in kidney. Immunohistochemical
analysis of kidney cortex sections confirmed the intense
basolateral expression of Ca2+-sensing receptor in TAL.
Moreover, we demonstrated that the Ca2+-sensing recep-
tor is present in DCT and CNT, confirming previous ob-
servations [10, 36]. However, the acute hypocalcaemic
response to the type II calcimimetic compound NPS R-
568 was abolished in (thyro) parathyroidectomized rats
infused with Ca2+ or PTH, suggesting that the effects of
the calcimimetic compounds are totally dependent on the
parathyroid Ca2+-sensing receptor–mediated inhibition
of PTH secretion [29, 37]. In addition, pharmacologic evi-
dence from a study using NPS R-467 in rats suggested that
renal Ca2+-sensing receptor contributes to the regulation
of Ca2+ reabsorption by modulating the response to PTH
rather than by affecting transport mechanisms directly
[abtstract; Fox, et al, J Am Soc Nephrol SA-FC179, 2003].
Nevertheless, in the present study, the calcimimetic com-
pound NPS R-467 could directly affect serum Ca2+ levels
via inhibitory actions on the renal Ca2+-sensing receptor.
Remarkably, after NPS R-467 treatment Ca2+-sensing re-
ceptor mRNA levels were down-regulated, which could
indeed mediate the decreased expression of Ca2+ trans-
port proteins by directly affecting expression or by
modulating the effect of PTH [38, 39]. However, parathy-
roidectomy in rats did not change the Ca2+-sensing
receptor mRNA levels, suggesting that differences in
Ca2+-sensing receptor expression are not entirely respon-
sible for the observed effect on renal Ca2+ transport
proteins. In addition to abundance, the activity of the
Ca2+-sensing receptor could play a role in directly affect-
ing Ca2+ transporter expression. It is unlikely that Ca2+-
sensing receptors on parathyroid cells and kidney cells are
exposed to different levels of NPS R-467. However, the
cellular environment in which the receptor is expressed
could profoundly influence its response to ligands. This
has already been established for G protein–coupled re-
ceptors as well as for the different effects of calcimimetics
on PTH and calcitonin secretion [37, 40]. Studies of in-
herited disorders caused by mutations in Ca2+-sensing
receptor clearly suggest that this receptor is the mecha-
nism for Ca2+-mediated regulation of both PTH secre-
tion and Ca2+ excretion by the kidney [28]. However, no
data are present about the physiologic function of the
Ca2+-sensing receptor in DCT/CNT and its possible ef-
fect on Ca2+ reabsorption. Our findings suggest that there
are additional or alternative mechanisms to account for
the altered renal Ca2+ handling, involving PTH-mediated
regulation of the expression of renal Ca2+ transport
proteins.
In various studies exploring the regulatory role of
1,25(OH)2D3, estrogens, PTH, and dietary Ca2+, we
observed the concomitant up-regulation of Ca2+ trans-
port proteins in kidney [19, 32]. Likewise, genetic
ablation of TRPV5 in mouse resulted in a decreased
expression of calbindin-D28K and NCX1. As transcel-
lular Ca2+ reabsorption in DCT/CNT was abolished
in these TRPV5 knockout mice, the concomitant de-
crease in Ca2+ transport proteins, even in the presence of
elevated 1,25(OH)2D3 levels, suggested a regulatory
mechanism controlled primarily by TRPV5 [26]. We,
therefore, hypothesized that the Ca2+ influx through
TRPV5 predominantly controls the expression of
the downstream Ca2+ transport proteins. To further
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substantiate the effect of PTH on Ca2+ influx, rabbit pri-
mary cell cultures were used. These cultures retain many
characteristics of the original epithelium, including a net
apical-to-basolateral Ca2+ transport and hormone re-
sponsiveness [13]. In rabbit, the CNT and CCD have
been implicated in active Ca2+ reabsorption and it
has been shown that the transcellular Ca2+ transport
proteins are all present in these cells [5, 18, 21, 41].
Using polarized monolayers of the rabbit CNT/CCD, we
demonstrated that PTH stimulates transepithelial Ca2+
transport, which was accompanied by an increased ex-
pression of TRPV5, calbindin-D28K, and NCX1. Subse-
quently, the entry of Ca2+ through TRPV5 was blocked
with ruthenium red, which is a potent inhibitor of TRPV5
with an inhibition constant (IC50) of around 110 nmol/L
[14]. Blockage of TRPV5 by ruthenium red eliminated
PTH-stimulated transepithelial Ca2+ transport and si-
multaneously decreased the expression of calbindin-D28K
and NCX1, whereas TRPV5 expression remained unaf-
fected. Apparently, there are two mechanisms that are
responsible for the effect on calbindin-D28K and NCX1
expression in the primary CNT and CCD cell monolay-
ers. The magnitude of the Ca2+ influx through TRPV5
predominantly controls the expression of calbindin-D28K
and NCX1. In addition, direct stimulation by PTH results
in increased expression of TRPV5, calbindin-D28K, and
NCX1.
Taken together, our findings imply that the magnitude
of the Ca2+ influx through TRPV5 controls the expres-
sion of the Ca2+ transport proteins. In addition, these
results confirm the direct effect of PTH on the expres-
sion of these renal proteins. Moreover, they explain the
coordinated regulation of the renal Ca2+ transport pro-
teins and further emphasize the gatekeeper function of
TRPV5.
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